MARKET

PSTI

PSTI

Pluristem Ther
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.260
+0.030
+2.44%
After Hours: 1.200 -0.06 -4.76% 19:59 07/01 EDT
OPEN
1.220
PREV CLOSE
1.230
HIGH
1.300
LOW
1.220
VOLUME
52.89K
TURNOVER
0
52 WEEK HIGH
4.050
52 WEEK LOW
1.060
MARKET CAP
40.76M
P/E (TTM)
-0.8598
1D
5D
1M
3M
1Y
5Y
10 Best Biotech Penny Stocks To Buy Now
In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of the biotech sector, go directly to 5 Best Biotech Penny Stocks To Buy Now. Like all sectors of the economy right now, the biotech sector i...
Insider Monkey · 06/20 13:22
10 Biotech Penny Stocks with Growth Catalysts
In this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 wa...
Insider Monkey · 04/06 14:15
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Is...
GlobeNewswire · 03/28 07:00
Pluristem's PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients
Benzinga · 03/23 16:35
Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial
Pluristem Therapeutics (NASDAQ:PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). The company said
Seekingalpha · 03/23 15:59
BRIEF-Pluristem Releases Plx-R18 Hematology Phase I Study Results Data Show Increase In All Blood Lines And Reduction In Blood Transfusions
reuters.com · 03/23 11:39
Pluristem Released PLX-R18 Hematology Phase I Study Results; Data Show Increase in All Blood Lines and Reduction in Blood Transfusions Said PLX-R18 Reduced Mortality From 29% to 18% and Was Well-tolerated With a Favorable Safety Profile
Pluristem Therapeutics Inc.
Benzinga · 03/23 11:33
Pluristem Therapeutics Reports Positive Data From Phase 1 Study of PLX-R18
MT Newswires · 03/23 08:12
More
No Data
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem Ther through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PSTI stock price target is 7.17 with a high estimate of 9.50 and a low estimate of 3.000.
High9.50
Average7.17
Low3.000
Current 1.260
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 2.20M
% Owned: 6.79%
Shares Outstanding: 32.35M
TypeInstitutionsShares
Increased
9
208.42K
New
7
83.40K
Decreased
9
357.66K
Sold Out
15
1.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Director
Rami Levi
Director
Varda Shalev
Independent Director
Doron Birger
Independent Director
Maital Shemesh-Rasmussen
No Data
No Data
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.